COLLEGIUM PHARMACEUTICAL, INC 8-K

What Happened
On May 7, 2026, Collegium Pharmaceutical, Inc. announced its financial results for the quarterly period ended March 31, 2026. The company furnished a press release (Exhibit 99.1) under Item 2.02 (Results of Operations and Financial Condition) and an earnings presentation (Exhibit 99.2) under Item 7.01 (Regulation FD Disclosure) to the SEC; both exhibits were furnished, not filed. The 8-K was signed by Colleen Tupper, Executive Vice President and Chief Financial Officer.

Key Details

• Announcement date: May 7, 2026.
• Reporting period: Quarterly period ended March 31, 2026.
• Exhibits: Press Release (Exhibit 99.1) and Earnings Presentation (Exhibit 99.2) were furnished to the SEC.
• Form 8-K filed and signed by Colleen Tupper, EVP & CFO.

Why It Matters
This 8-K signals that Collegium has released its latest quarterly earnings and supporting presentation — primary sources for updated revenue, profit/loss, and operating highlights. Retail investors should review the attached press release and presentation for the company’s reported financial results, trends, and any commentary on outlook or key business drivers. Note that the materials were “furnished, not filed,” meaning they were provided to the SEC for disclosure but are typically not subject to the same liabilities as formally filed statements.